Literature DB >> 28323156

Prognostic significance of the number of lymph nodes examined in node-negative Siewert type II esophagogastric junction adenocarcinoma.

Xian-Ning Wu1, Chang-Qing Liu1, Jie-Yong Tian1, Ming-Fa Guo1, Mei-Qing Xu2.   

Abstract

BACKGROUND: Involvement status of lymph node (LN) is one of the most important prognostic factors for esophagogastric junction (EGJ) adenocarcinoma. However, the prognostic value of the number of examined LNs remains unclear in node-negative (pN0) Siewert type II EGJ adenocarcinoma.
METHODS: A cohort of 262 patients who underwent curative surgery for pN0 Siewert type II EGJ adenocarcinoma from January 2000 to August 2013 were retrospectively analyzed from high-volume center database. All enrolled patients were categorized into 3 groups according to the number of examined LNs (≤14, 15 to 21, ≥22). Kaplan-Meier curves were used for comparing the differences of cancer-specific survival among groups; Correlation between survival and the number of examined LNs were analyzed by using stratified, uni- and multivariate analyses.
RESULTS: The hazard ratio for cancer-specific mortality decreased sequentially with increasing number of LNs examined. The 5-year cancer-specific survival rates were 45.1%, 58.4% and 65.7% for patients with ≤14 LNs, 15 to 21 and ≥ 22 LNs removed, respectively. The number of removed LNs was significantly correlated with survival in stratified analyses according to T stage. In multivariate model controlling for gender, age, surgical approach, tumor grade, and postoperative chemotherapy, the number of removed LNs and T stage were confirmed to be independent prognostic factors and significantly correlated with disease-specific survival.
CONCLUSION: The number of examined LNs is an independent prognostic factor of survival for patients with pN0 Siewert type II EGJ adenocarcinoma. Adequate dissection of LNs (more than 15 LNs) is recommended for patients undergoing curative resection.
Copyright © 2017. Published by Elsevier Ltd.

Entities:  

Keywords:  Adenocarcinoma; Esophagogastric junction; Lymph nodes; Prognosis; Retrospective studies

Mesh:

Year:  2017        PMID: 28323156     DOI: 10.1016/j.ijsu.2017.03.028

Source DB:  PubMed          Journal:  Int J Surg        ISSN: 1743-9159            Impact factor:   6.071


  6 in total

1.  Lymph Node Ratio Is an Independent Prognostic Factor for Patients with Siewert Type II Adenocarcinoma of Esophagogastric Junction: Results from a 10-Year Follow-up Study.

Authors:  Yuling Zhang; Ditian Liu; Chunfa Chen
Journal:  J Gastrointest Cancer       Date:  2021-09

2.  Short-term postoperative complications and prognostic factors in patients with adenocarcinoma of the esophagogastric junction.

Authors:  Hui Zhang; WeiJian Zhang; DeFeng Peng; JinHai Zhu
Journal:  Thorac Cancer       Date:  2018-06-21       Impact factor: 3.500

Review 3.  Current surgical treatment of esophagogastric junction adenocarcinoma.

Authors:  Shun Zhang; Hajime Orita; Tetsu Fukunaga
Journal:  World J Gastrointest Oncol       Date:  2019-08-15

4.  Prognostic Significance of CIP2A in Esophagogastric Junction Adenocarcinoma: A Study of 65 Patients and a Meta-Analysis.

Authors:  Yanhong Li; Mei Wang; Xueping Zhu; Xu Cao; Yi Wu; Fang Fang
Journal:  Dis Markers       Date:  2019-08-22       Impact factor: 3.434

5.  Tumor-Targeted Polydopamine-Based Nanoparticles for Multimodal Mapping Following Photothermal Therapy of Metastatic Lymph Nodes.

Authors:  Yanrui Liang; Weihong Guo; Chuangji Li; Guodong Shen; Haoxian Tan; Peiwen Sun; Zhian Chen; Huilin Huang; Zhenhao Li; Zhenyuan Li; Yingxin Ren; Guoxin Li; Yanfeng Hu
Journal:  Int J Nanomedicine       Date:  2022-09-29

6.  Adequate Lymphadenectomy as a Quality Measure in Esophageal Cancer: Is there an Association with Treatment Approach?

Authors:  Cary Jo R Schlick; Rhami Khorfan; David D Odell; Ryan P Merkow; David J Bentrem
Journal:  Ann Surg Oncol       Date:  2020-06-09       Impact factor: 4.339

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.